在一次小试验显示其WSD4000凝胶显著改善了女性的性功能后,Futura医疗股份增加了11%。 Futura Medical shares rose 11% after a small trial showed its WSD4000 gel significantly improved female sexual function.

Futura Medical PLC股份在2026年1月12日上升11%至1.45p, 该公司报告说, Futura Medical PLC shares rose 11% to 1.45p on January 12, 2026, after the company reported promising early results from a small trial of its WSD4000 gel for female sexual dysfunction. 这项研究涉及12名女性,遵循FDA的指导方针,显示性功能有"非常显著的"改善,平均FSFI得分增加6. 35分,超过了临床上有意义的值. The study, involving 12 women and following FDA guidelines, showed “highly statistically significant” improvements in sexual function, with an average FSFI score increase of 6.35 points—exceeding the clinically meaningful threshold. 这些结果虽然是初步的,但引起了投资者的兴趣,并表明有可能进行场外治疗。 The results, while preliminary, have generated investor interest and suggest potential for an over-the-counter treatment. 该公司继续通过早期研究来推进产品。 The company continues advancing the product through early-stage research.